Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer

Figure 1

Progression-free survival (PFS) (a) and overall survival (OS) (b) in NLR quartile.

(a)

(b)